{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:44:08Z","timestamp":1760402648636,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic series describe long-term disease-free survival in stage III disease treated with wide-field radiation therapy (WFRT), encompassing all known disease sites. We report outcomes for patients staged with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and treated with CT-planned WFRT, given as either comprehensive lymphatic irradiation (CLI) or total nodal irradiation (TNI). This analysis of a prospective cohort includes PET-staged patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24\u201330Gy between 1999 and 2017. Fifteen patients also received planned systemic therapy (containing rituximab in 11 cases) as part of their primary treatment. At 10 years, overall survival and freedom from progression (FFP) were 100% and 75%, respectively. None of the 11 rituximab-treated patients have relapsed. Nine relapses occurred; seven patients required treatment, and all responded to salvage therapies. A single death occurred at 16 years. The principal acute toxicity was transient hematologic; one patient had residual grade two toxicity at one year. With FDG-PET staging, most patients with stage III FL experience prolonged FFP after WFRT, especially when combined with rituximab.<\/jats:p>","DOI":"10.3390\/cancers12040991","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T05:48:52Z","timestamp":1587448132000},"page":"991","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy"],"prefix":"10.3390","volume":"12","author":[{"given":"Michael P.","family":"MacManus","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Department of Molecular Imaging, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics and Clinical trials, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8723","authenticated-orcid":false,"given":"Belinda A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Wolf","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Department of Haematology, Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Hoppe","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: Involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00066-010-2090-9","article-title":"Nodal follicular lymphoma: The role of radiotherapy for stages I and II","volume":"186","author":"Heinzelmann","year":"2010","journal-title":"Strahlenther. Onkol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: Evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0b013e328365a151","article-title":"Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: Indications and outcomes","volume":"20","author":"Rezvani","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/10428199309149108","article-title":"Combination chemotherapy in the treatment of follicular low-grade lymphoma","volume":"10","author":"Morrison","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3324\/haematol.2012.069583","article-title":"Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: Potential benefit in second relapse","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/10428194.2011.613132","article-title":"The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma","volume":"53","author":"Andresen","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1470-2045(11)70181-4","article-title":"The challenge of recurrent follicular lymphoma","volume":"12","author":"Tomas","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00000421-198906000-00002","article-title":"Comprehensive lymphatic irradiation for stage II-III non-Hodgkin\u2019s lymphoma","volume":"12","author":"Mendenhall","year":"1989","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JCO.1993.11.2.233","article-title":"Central lymphatic irradiation for stage III nodular malignant lymphoma: Long-term results","volume":"11","author":"Jacobs","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(00)00780-X","article-title":"Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University","volume":"49","author":"Murtha","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1748-717X-7-103","article-title":"Radiotherapy alone for stage I-III low grade follicular lymphoma: Long-term outcome and comparison of extended field and total nodal irradiation","volume":"7","author":"Guckenberger","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.1984.2.7.841","article-title":"The role of radiation therapy in the management of stage III follicular lymphomas","volume":"2","author":"Paryani","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.1987.5.6.867","article-title":"Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen","volume":"5","author":"McLaughlin","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0360-3016(00)00481-8","article-title":"Salvage extended-field irradiation in follicular non-Hodgkin\u2019s lymphoma after failure of chemotherapy","volume":"47","author":"Mahe","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0360-3016(03)00592-3","article-title":"Central lymphatic irradiation for stage I-III follicular lymphoma: Report from a single-institutional prospective study","volume":"57","author":"Ha","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00631-1","article-title":"Is comprehensive lymphatic irradiation for low-grade non-Hodgkin\u2019s lymphoma curative therapy? Long-term experience at a single institution","volume":"38","author":"Mendenhall","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdg055","article-title":"Australasian Leukaemia Lymphoma, G. Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma","volume":"14","author":"Campbell","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: A collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/bloodadvances.2019000458","article-title":"Outcomes of stage I\/II follicular lymphoma in the PET era: An international study from the Australian Lymphoma Alliance","volume":"3","author":"Tobin","year":"2019","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1470-2045(14)70066-X","article-title":"Follicular lymphoma: Watch and wait is watch and worry","volume":"15","author":"Ansell","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"104","author":"Mikhaeel","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study","volume":"2","author":"Herfarth","year":"2018","journal-title":"Hemasphere"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2003.07.054","article-title":"Positron Emission Tomography is superior to CT scanning for response-assessment after radical radiotherapy\/chemoradiotherapy in patients with non-small cell lung cancer","volume":"21","author":"Matthews","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2004.11.024","article-title":"Metabolic (FDG-PET) response after radical radiotherapy\/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure","volume":"49","author":"Hicks","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: Issues in delineating the radiation field in Hodgkin\u2019s disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/991\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:44:58Z","timestamp":1760363098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12040991"],"URL":"https:\/\/doi.org\/10.3390\/cancers12040991","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2020,4,17]]}}}